Semaglutide Once a Week in Adults With Overweight or Obesity, With or Without Type 2 Diabetes in an East Asian Population (STEP 6): A Randomised, Double-Blind, Double-Dummy, Placebo Controlled, Phase 3a Trial

Lancet Diabetes Endocrinol 2022;10:193–206. doi.org/10.1016/S2213-8587(22)00008-0

In this Phase 3a trial in an east Asian population, semaglutide 2.4 mg QW was shown to have superior and clinical meaningful reductions in bodyweight versus placebo, as well as greater reductions in abdominal visceral fat.

While the weight management effects of semaglutide 2.4 mg QW have been studied in a global population, Asian populations differ in terms of body composition and obesity definitions. Therefore, the STEP 6 trial was undertaken to assess the effect of semaglutide versus placebo in an east Asian population.


LinkedIn